TD Cowen has released its slate of preferred SMIDCAP investments for 2026, singling out names in the small- and mid-cap segment that the firm believes combine structural growth opportunities with catalysts that could drive share-price outperformance. At the top of the list is UroGen Pharma (NASDAQ:URGN), where TD Cowen’s recommendation centers on the commercial and clinical momentum behind the company’s product Zusduri.
Market potential and sales scenarios
TD Cowen’s analysis puts particular emphasis on the market adoption trajectory for Zusduri. Key opinion leaders surveyed by the firm consistently point to possible peak penetration rates in the range of 30% to 40% among the relevant low-grade/intermediate-risk non-muscle invasive bladder cancer (LG/IR NMIBC) population, with some respondents indicating expectations for even broader use. Those prevalence assumptions imply potential peak annual sales in excess of $2 billion, a figure TD Cowen describes as potentially conservative.
The current calendar year is framed as pivotal. TD Cowen expects reported sales in the range of $120 million to $150 million for the year, which the firm views as a necessary validation point to confirm the therapy’s commercial trajectory.
Clinical differentiation and real-world uptake
The research note highlights substantial clinical evidence that shows Zusduri to be a meaningful improvement compared with repeated transurethral resection of bladder tumor (TURBT) on multiple fronts - efficacy, durability, safety, and patient convenience. The company’s transition to a permanent J-code on January 1 is credited with accelerating the launch, reflected in higher patient starts, increasing doses administered, and broader prescriber adoption. TD Cowen notes meaningful month-over-month growth during the rollout.
Physician behavior in the field appears to be shifting as clinicians gain experience with real-world outcomes. Accounts are moving toward treating multiple patients with Zusduri, and approximately 40% of prescribers are now dosing more than one patient, an indicator the firm interprets as growing prescriber confidence.
Modeling assumptions and physician expectations
While management’s framework and TD Cowen’s conservative modeling point to roughly $1 billion in peak sales based on sub-20% penetration, the firm also reports that providers surveyed regularly suggest 30-40% penetration could be attainable. TD Cowen attributes the potential for higher uptake to Zusduri’s differentiated profile: strong complete response rates coupled with unusually long durability after a finite six-week regimen that does not require maintenance dosing.
Durability is emphasized as a key, and possibly underappreciated, advantage. In available long-term follow-up data, the median duration of response for Zusduri was not reached at roughly 36 months of follow-up, compared with typical TURBT durability benchmarks of 7-14 months.
Pipeline and lifecycle programs
Beyond the lead asset, TD Cowen identifies UGN-103 as an important lifecycle-management program. The firm reports that UGN-103 has shown efficacy consistent with Zusduri and is expected to support a launch targeted for 2028. TD Cowen suggests UGN-103 could extend the mitomycin franchise beyond its current intellectual-property horizon and enable expansion into papillary high-grade NMIBC and adjuvant intermediate-risk NMIBC. Additionally, UGN-501 is described as providing further upside potential through a next-generation oncolytic virus platform.
Legal development and analyst responses
UroGen announced a patent litigation settlement with Teva Pharmaceuticals concerning its JELMYTO product. In the wake of that development, both H.C. Wainwright and Oppenheimer reaffirmed their positive ratings on the company, a reaction TD Cowen references in its broader appraisal.
Implications for SMIDCAP investors
TD Cowen’s pick of UroGen as its leading SMIDCAP idea for 2026 underscores the firm’s view that differentiated clinical outcomes and accelerating real-world adoption can reshape commercial expectations for a small-cap biotech. The firm balances a conservative internal sales case against more bullish physician feedback, and it highlights pipeline extensions that could broaden addressable markets. For investors focused on the healthcare and small-cap equity spaces, the note frames UroGen as a company where clinical durability and launch execution will be critical monitors of future valuation.
Data and disclosures
The report centers on TD Cowen’s published views and on company-reported clinical and launch statistics. It references expected sales ranges, physician survey data, clinical follow-up duration, pipeline timelines, and the existence of a patent litigation settlement—all items noted in the firm’s analysis.